Dapiprazole

This classification denotes an alpha-adrenergic blocking agent with the molecular formula C19H27N5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5RNZ8GJO7K, chemically known as 5,6,7,8-tetrahydro-3-(2-(4-o-tolyl-1-piperazinyl)ethyl)-s-triazolo(4,3-a)pyridine monohydrochloride but generally known as dapiprazole, which bears US NIH Compound Identifier 91269. European Medicines Agency schedules Dapiprazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06906MIG. The term DAPIPRAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). World Health Organization schedules dapiprazole in its Anatomical Therapeutic Chemical (ATC) Classification. DAPIPRAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dapiprazole under HS 29335995 and SITC 51576. As of Q4 2014, DAPIPRAZOLE remains the US FDA Preferred Term for this commodity. Dapiprazole bears US NLM identifiers UMLS ID C0057143 and NCI Concept Code C83648. SMILES: CL.N12CCCCC1NNC2CCN1CCN(CC1)C1C(CCCC1)C.